D. Paraïso - Concepedia

Author

D. Paraïso

Hôtel-Dieu de Paris

Also Known As

D Paraiso, D. PARAISO, D. Paraiso, D. Paraïso, D.I. Paraiso, Désiré Paraiso, D�sir� Paraiso, I Ray-Coquard, N Dohollou

Publications

Citations

H-Index

Concepts

All Affiliations

Hôtel-Dieu de Paris Délégation Centre-Est Assistance Publique – Hôpitaux de Paris Centre Hospitalier de l'Agglomération de Nevers Université Paris Cité

About

D. Paraïso is an author at Hôtel-Dieu de Paris specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	628
2	Obstetrics	11	11	473
3	Public Health	2	2	98
4	Health Sciences	1	1	30
5	Anatomy	1	1	20

D. Paraïso

Publications

938

Citations

H-Index

Page 1

	Year	Citations
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group Sophie Camilleri‐Broët, Anne‐Claire Hardy‐Bessard, A. Le Tourneau, Annals of Oncology	2003	109
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Jean-Marc Ferrero, B. Weber, J.-F. Geay, Annals of Oncology Pegylated Liposomal DoxorubicinLate RelapseMedicinePharmacologyGynecology	2006	105
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Isabelle Ray‐Coquard, Laure Favier, B. Weber, British Journal of Cancer	2013	102
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) Alain Lortholary, R. Largillier, B. Weber, Annals of Oncology Resistant Ovarian CancerOncologyWeekly TopotecanMedicineGynecology	2011	92
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial J.E. Kurtz, Anne‐Claire Hardy‐Bessard, Marion Deslandres, Gynecologic Oncology Advanced Cervical CancerCervical Cancer ManagementCervical CancerMedicineMetronomic Therapy	2009	85
Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study H. Curé, Claudia Battista, Jean‐Paul Guastalla, Journal of Clinical Oncology Surgical OncologyCancer ManagementGynecologyPathologyGynecology Oncology	2004	45
Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study Arash Rafii, Bruno Deval, J.-F. Geay, International Journal of Gynecological Cancer	2007	38
Management of rare ovarian cancers: The experience of the French website «Observatory for rare malignant tumours of the ovaries» by the GINECO group: Interim analysis of the first 100 patients Isabelle Ray‐Coquard, B. Weber, Jean Pierre Lotz, Gynecologic Oncology Interim AnalysisTumoral PathologyGynecological SurgeryRare Ovarian CancersMedicine	2010	36
Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial Claire Falandry, Étienne Brain, Marc Bonnefoy, European Journal of Cancer Final ResultsBreast OncologyOncologyLiposomal Doxorubicin ToleranceMedicine	2013	30

Page 1